Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 87.9% | -11.1% | 207.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.9% | 94% | 95% | 82.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -400.9% | -719.5% | -327.7% | -1,402% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -401.6% | -720.3% | -326.9% | -1,395.1% |
| EPS Diluted | -0.014 | -0.017 | -0.009 | -0.015 |
| % Growth | 20.6% | -84.8% | 38.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |